Scynexis debuts Brexafemme

Scynexis is introducing Brexafemme (ibrexafungerp tablets), the first and only oral non-azole prescription medication approved by the Food and Drug Administration to treat vulvovaginal candidiasis, commonly referred to as vaginal yeast infection.

“It’s incredibly exciting for all of us at Scynexis to bring this innovative antifungal treatment to the millions of women across the country who suffer from yeast infections,” said Marco Taglietti, president and CEO of Scynexis. “This approval is just the first step to potentially building a wide-ranging ibrexafungerp antifungal franchise in multiple indications for broad patient community infections and in the hospital setting for life-threatening invasive fungal infections.”

[Read more: FDA approves Scynexis' Brexafemme]

Brexafemme, a one-day oral medication consisting of two pills (150 mg each) in the morning and two in the evening, is the first new antifungal class in more than 20 years, the company noted.

Christine Coyne, Scynexis chief commercial officer said, “Despite the fact that vaginal yeast infections are extremely common with about three out of four women experiencing them at least once in their life, until now there had been limited advancement in this area of women’s health for  decades. Brexafemme is a truly new, first-in-class fungicidal triterpenoid antifungal, designed to kill the yeast causing the infection, including azole-resistant strains.”

[Read more: Hum Nutrition's Private Party focuses on vaginal, urinary tract health]